FibroGen (FGEN) Misses Q2 EPS by 20c

FibroGen (NASDAQ: FGEN) reported Q2 EPS of ($0.90), $0.20 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $44.32 million versus the consensus estimate of $34.73 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Apple’s big price hike seen as "an unprecedented push to protect margins"
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance